Chronic hypertension resident survival guide: Difference between revisions
No edit summary |
|||
(13 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
<div style="width: 80%;"> | <div style="width: 80%;"> | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{AE}} {{AO}} | {{CMG}}; {{AE}} {{AO}} | ||
{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 0 0 30px 30px;" cellpadding="0" cellspacing="0"; | {| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 0 0 30px 30px;" cellpadding="0" cellspacing="0" ; | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background: #A8A8A8" align=center| {{fontcolor|#2B3B44|Hypertension Resident Survival Guide Microchapters}} | ! style="padding: 0 5px; font-size: 85%; background: #A8A8A8" align="center" | {{fontcolor|#2B3B44|Hypertension Resident Survival Guide Microchapters}} | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[Chronic hypertension resident survival guide#Overview|Overview]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[Chronic hypertension resident survival guide#Classification|Classification]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[Chronic hypertension resident survival guide#Causes|Causes]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |Diagnosis | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |Diagnosis | ||
:[[ | :[[Chronic hypertension resident survival guide#General Approach|General]] | ||
:[[ | :[[Chronic hypertension resident survival guide#Complete Diagnostic Approach|Complete]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | Treatment | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | Treatment | ||
:[[ | :[[Chronic hypertension resident survival guide#Prehypertension|Prehypertension]] | ||
:[[ | :[[Chronic hypertension resident survival guide#Stage 1 Hypertension|Stage 1]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | Medical Therapy | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | Medical Therapy | ||
:[[ | :[[Chronic hypertension resident survival guide#Choice of Regimen|Choice of Regimen]] | ||
:[[ | :[[Chronic hypertension resident survival guide#Drug List|Drug List]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[Chronic hypertension resident survival guide#Don'ts|Don'ts]] | ||
|} | |} | ||
==Overview== | ==Overview== | ||
[[Hypertension]] (HTN) is defined as a [[systolic blood pressure]] (SBP) ≥ 140 mmHg and [[diastolic blood pressure]] (DBP) ≥ 90 mmHg.<ref name="pmid14656957">{{cite journal| author=Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al.| title=Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. | journal=Hypertension | year= 2003 | volume= 42 | issue= 6 | pages= 1206-52 | pmid=14656957 | doi=10.1161/01.HYP.0000107251.49515.c2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14656957 }} </ref> It is usually detected during the screening of an asymptomatic individual, but the diagnosis is based on persistent elevation of [[blood pressure]] after | [[Hypertension]] (HTN) is defined as a [[systolic blood pressure]] (SBP) ≥ 140 mmHg and [[diastolic blood pressure]] (DBP) ≥ 90 mmHg.<ref name="pmid14656957">{{cite journal| author=Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al.| title=Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. | journal=Hypertension | year= 2003 | volume= 42 | issue= 6 | pages= 1206-52 | pmid=14656957 | doi=10.1161/01.HYP.0000107251.49515.c2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14656957 }} </ref> It is usually detected during the screening of an asymptomatic individual, but the diagnosis is based on persistent elevation of [[blood pressure]] after an average of 2 or more [[blood pressure]] measurements taken during 2 or more health care visits. [[Hypertension]] is classified as either primary (or essential) when the etiology cannot be identified; or secondary, when the etiology (e.g., [[hyperthyroidism]], [[pheochromocytoma]], [[renal artery stenosis]]) is known. The presence of [[diabetes mellitus]], [[Health effects of tobacco smoking|cigarette smoking]], excessive [[sodium]] intake, [[obesity]], and [[sedentary lifestyle]] increases the risk of developing [[essential hypertension]]. Lifestyle modifications such as [[Weight loss|weight reduction]], reduction in [[alcohol]] consumption, [[exercise]]s, and reduction in salt intake are recommended to all patients in addition to pharmacological therapy, when required. | ||
==Classification== | ==Classification== | ||
{|class="wikitable" | The ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA 2017 [[clinical practice guidelines]]<ref name="pmid29133356">{{cite journal| author=Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al.| title=2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. | journal=Hypertension | year= 2017 | volume= | issue= | pages= | pmid=29133356 | doi=10.1161/HYP.0000000000000065 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29133356 }} </ref>, executive summary<ref name="pmid29133354">{{cite journal| author=Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al.| title=2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. | journal=Hypertension | year= 2017 | volume= | issue= | pages= | pmid=29133354 | doi=10.1161/HYP.0000000000000066 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29133354 }} </ref>, and underlying [[systematic review]]<ref name="pmid29133354">{{cite journal| author=Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al.| title=2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. | journal=Hypertension | year= 2017 | volume= | issue= | pages= | pmid=29133354 | doi=10.1161/HYP.0000000000000066 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29133354 }} </ref> by the ACC/AHA taskforce recommend a treatment goal for everyone is <130/80 mm Hg: | ||
! | |||
{| class="wikitable" | |||
! | |||
! Definition | |||
! Treatment | |||
|- | |- | ||
| Normal | |Normal blood pressure | ||
|<120/80 mmHg | |||
|Lifestyle | |||
|- | |- | ||
| | | Elevated blood pressure | ||
| Systolic BP, 120–129 mm Hg<br /> - and -<br />Diastolic BP, <80 mm Hg<br /> | |||
| Lifestyle | |||
|- | |- | ||
| Stage 1 hypertension|| | | Stage 1 hypertension | ||
| Systolic BP, 130–139 mm Hg<br /> - or -<br />Diastolic BP, 80–89 mm Hg<br /> | |||
| Lifestyle and<br />Medications if high risk* | |||
|- | |- | ||
| Stage 2 hypertension| | | Stage 2 hypertension<br /> | ||
| Systolic BP, ≥140 mm Hg<br /> - or -<br />Diastolic BP, ≥90 mm Hg | |||
| Lifestyle and<br />Medications | |||
|- | |- | ||
| [[ | | colspan="3" | * High risk defined as existing cardiovascular disease or 10-year cardiovascular risk ≥10% ([http://www.cvriskcalculator.com/ calculator] and [https://openrules.ocpu.io/home/www/statins_for_cvd.html alternative calculator with facts box]) | ||
|} | |} | ||
Line 137: | Line 145: | ||
❑ Take repeated measurements in patients with [[arrhythmia]]<br> | ❑ Take repeated measurements in patients with [[arrhythmia]]<br> | ||
❑ Measure [[blood pressure]] at both arms at first visit to detect possible differences<br> | ❑ Measure [[blood pressure]] at both arms at first visit to detect possible differences<br> | ||
<br>Click '''[[Hypertension blood pressure measurement|here for more information regarding blood pressure measurement]]'''</div>}} | |||
Click '''[[Hypertension blood pressure measurement|here for more information regarding blood pressure measurement]]'''}} | |||
{{familytree | | | | | |!| | |}} | {{familytree | | | | | |!| | |}} | ||
{{familytree | | | | | C01 | | C01=For '''office BP >140/90 mmHg''' on 2-3 visits}} | {{familytree | | | | | C01 | | C01=For '''office BP >140/90 mmHg''' on 2-3 visits}} | ||
Line 144: | Line 151: | ||
{{familytree | | | | | D01 | | | | D01=Does the patient have any evidence of target organ damage, [[DM]], or [[CKD]]?}} | {{familytree | | | | | D01 | | | | D01=Does the patient have any evidence of target organ damage, [[DM]], or [[CKD]]?}} | ||
{{familytree | | | |,|-|^|-|.| | |}} | {{familytree | | | |,|-|^|-|.| | |}} | ||
{{familytree | | | E01 | | E02 | | E01=Yes|E02=No}} | {{familytree | | | E01 | | E02 | | |E01=Yes|E02=No}} | ||
{{familytree | | | |!| | | |!| | | | |}} | {{familytree | | | |!| | | |!| | | | |}} | ||
{{familytree | | | F01 | | F02 | | | | |F01=Proceed to '''[[hypertensive crisis resident survival guide]]'''|F02=Perform home BP/out-of-office monitoring}} | {{familytree | | | F01 | | F02 | | | | |F01=Proceed to '''[[hypertensive crisis resident survival guide]]'''|F02=Perform home BP/out-of-office monitoring}} | ||
Line 156: | Line 163: | ||
{{familytree | | | |!| | | J01 | | |!| | |J01=Is the 24-hour [[Ambulatory blood pressure monitoring|ABPM]] ≤135/85?}} | {{familytree | | | |!| | | J01 | | |!| | |J01=Is the 24-hour [[Ambulatory blood pressure monitoring|ABPM]] ≤135/85?}} | ||
{{familytree | | | |!| |,|-|^|-|.| |!| | |}} | {{familytree | | | |!| |,|-|^|-|.| |!| | |}} | ||
{{familytree | | {{familytree | | | |!| K02 | | K03 |!| | |K02=Yes|K03=No|}} | ||
{{familytree | |!| | | | | | | | | | | | | {{familytree | | | |!| |!| | | |`|v|'| | | |}} | ||
{{familytree | L01 | | | | | | | | | | L02 | | | {{familytree | | | |`|v|'| | | | K04 | | | | | | | |K04=[[Hypertension]] confirmed}} | ||
{{familytree | {{familytree | | | | L01 | | | | |!| |L01=[[White coat hypertension]] confirmed}} | ||
{{familytree | {{familytree | | | | | | | | | | L02 | | |L02=Classify the patient<br> based on the BP reading}} | ||
{{familytree | {{familytree | | | | | | |,|-|-|-|+|-|-|-|.| | |}} | ||
{{familytree | {{familytree | | | | | | M01 | | M02 | | M03 | |M01='''SBP 120-139 mmHg'''<br>'''DBP 80-89 mmHg'''|M02='''SBP 149-159 mmHg'''<br>'''DBP 90-99 mmHg'''|M03='''SBP >160 mmHg'''<br>'''DBP >110 mmHg'''}} | ||
Proceed to '''[[hypertensive crisis resident survival guide]]'''}} | {{familytree | | | | | | |!| | | |!| | | |!| |}} | ||
{{familytree | | | | | | N01 | | N02 | | N03 | |N01=<div style="float: left; text-align: left; width: 15em;padding:1em;">'''[[Prehypertension]]'''</div>|N02=<div style="float: left; text-align: left; width: 15em; padding:1em;">'''Stage 1 hypertension'''</div><br>Proceed to the [[Hypertension resident survival guide#Complete Diagnostic Approach|'''complete diagnostic approach''']] below|N03=<div style="float: left; text-align: left; width: 15em; padding:1em;">'''Stage 2 hypertension'''<br><br>Proceed to '''[[hypertensive crisis resident survival guide]]'''</div>}} | |||
{{familytree/end}} | {{familytree/end}} | ||
Line 255: | Line 263: | ||
'''General examination:'''<br> | '''General examination:'''<br> | ||
❑ Calculate [[Body mass index|BMI]] <br> | ❑ Calculate [[Body mass index|BMI]] <br> | ||
❑ Moon face, truncal [[obesity]], striae (suggestive of [[ | ❑ Moon face, truncal [[obesity]], striae (suggestive of [[Cushing's disease]])<br> | ||
❑ [[Goitre]], [[exophthalmus]], [[pretibial myxedema]] (suggestive of [[Graves' disease]])<br> | ❑ [[Goitre]], [[exophthalmus]], [[pretibial myxedema]] (suggestive of [[Graves' disease]])<br> | ||
❑ Dry skin (suggestive of [[hypothyroidism]])<br> | ❑ Dry skin (suggestive of [[hypothyroidism]])<br> | ||
Line 278: | Line 286: | ||
❑ Absent or diminished femoral pulsation (suggestive of [[coarctation of aorta]])<br> | ❑ Absent or diminished femoral pulsation (suggestive of [[coarctation of aorta]])<br> | ||
❑ [[Pedal edema]] (suggestive of [[congestive heart failure]])<br> | ❑ [[Pedal edema]] (suggestive of [[congestive heart failure]])<br> | ||
'''Neurological examination:'''<br> | '''Neurological examination:'''<br> | ||
❑ Findings suggestive of [[hypertensive encephalopathy]]<br> | ❑ Delayed return of [[deep tendon reflex|deep tendon reflexes]] (suggestive of [[hypothyroidism]])<br>❑ Findings suggestive of [[hypertensive encephalopathy]]<br> | ||
:❑ [[Confusion]]<br> | :❑ [[Confusion]]<br> | ||
:❑ [[Altered mental status]] | :❑ [[Altered mental status]] | ||
<br> | <br> | ||
Line 292: | Line 298: | ||
❑ [[Complete blood count|CBC]] <br> | ❑ [[Complete blood count|CBC]] <br> | ||
:❑ [[Anemia]] (associated with [[chronic renal failure]])<br> | :❑ [[Anemia]] (associated with [[chronic renal failure]])<br> | ||
❑ [[Urinalysis]]<br> | ❑ [[Urinalysis]]<br> | ||
:❑ [[Proteinuria]] (suggestive of end organ damage)<br> | :❑ [[Proteinuria]] (suggestive of end organ damage)<br> | ||
Line 322: | Line 327: | ||
{{familytree | | | | D01 | | |D01='''Does the patient have an identifiable secondary etiology?'''}} | {{familytree | | | | D01 | | |D01='''Does the patient have an identifiable secondary etiology?'''}} | ||
{{familytree | | |,|-|^|-|.| | |}} | {{familytree | | |,|-|^|-|.| | |}} | ||
{{familytree | | F01 | | F02 | |F01= | {{familytree | | F01 | | F02 | |F01=No|F02=Yes}} | ||
{{familytree | | |!| | | |!| | |}} | {{familytree | | |!| | | |!| | |}} | ||
{{familytree | | G01 | | G02 | |G01=[[Primary hypertension]]|G02=[[Secondary hypertension]]}} | {{familytree | | G01 | | G02 | |G01=[[Primary hypertension]]|G02=[[Secondary hypertension]]}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Line 337: | Line 340: | ||
'''SBP 120-139 mmHg<br>DBP - 80-89 mmHg'''</div>}} | '''SBP 120-139 mmHg<br>DBP - 80-89 mmHg'''</div>}} | ||
{{familytree | | | |!| | |}} | {{familytree | | | |!| | |}} | ||
{{familytree | | | B01 | |B01 | {{familytree | | | B01 | |B01=<div style="float: left; text-align: left; width: 15em; padding:1em;"> | ||
❑ Initiate lifestyle modification<br> | |||
❑ Initiate | |||
❑ Follow-up/recheck blood pressure in one year<br> | ❑ Follow-up/recheck blood pressure in one year<br> | ||
❑ Ensure self-monitoring of [[blood pressure]]<br></div>}} | ❑ Ensure self-monitoring of [[blood pressure]]<br></div>}} | ||
Line 364: | Line 361: | ||
<br> | <br> | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | A01 | A01=<div style="float: left; text-align: left; width: 25em; padding:1em;">''' | {{familytree | | | | | | | | A01 | A01=<div style="float: left; text-align: left; width: 25em; padding:1em;">'''The following categories require pharmacological treatment according to JNC 8?:'''<br> | ||
---- | ---- | ||
❑ [[BP]] ≥ 150/90 mmHg in patients ≥ 60 years <br> | ❑ [[BP]] ≥ 150/90 mmHg in patients ≥ 60 years <br> | ||
Line 377: | Line 374: | ||
❑ [[BP]] < 140/90 mmHg in patients < 60 years<br> | ❑ [[BP]] < 140/90 mmHg in patients < 60 years<br> | ||
'''Patients with [[DM]] or [[CKD]]'''<br> | '''Patients with [[DM]] or [[CKD]]'''<br> | ||
❑ [[BP]] < 140/90 mmHg | ❑ [[BP]] < 140/90 mmHg<br></div>}} | ||
</div>}} | |||
{{familytree | | | | | | | | |!| | | |}} | {{familytree | | | | | | | | |!| | | |}} | ||
{{familytree | | | | | | | | C01 | | |C01=<div style="float: left; text-align: left; width: 25em; padding:1em;">'''Initiate lifestyle modification:'''<br> | {{familytree | | | | | | | | C01 | | |C01=<div style="float: left; text-align: left; width: 25em; padding:1em;">'''Initiate lifestyle modification:'''<br> | ||
Line 394: | Line 390: | ||
:❑ ≤ 1 drink/day for women<br> | :❑ ≤ 1 drink/day for women<br> | ||
❑ Regular aerobic physical activity (brisk walking, jogging, cycling, swimming) for at least 30 mins per day <br> | ❑ Regular aerobic physical activity (brisk walking, jogging, cycling, swimming) for at least 30 mins per day <br> | ||
</div>}} | </div>}} | ||
{{familytree | | | | | | | | |!| | | |}} | {{familytree | | | | | | | | |!| | | |}} | ||
Line 477: | Line 472: | ||
! Preferably combined with | ! Preferably combined with | ||
|- | |- | ||
| [[Thiazide diuretics]] || [[Chlorthalidone]] || 12.5, 12.5-25|| [[Heart failure]], [[systolic hypertension|isolated systolic hypertension]], black population|| [[ACE inhibitors]], [[ARBs]], [[calcium channel blockers]] | | rowspan="4" | [[Thiazide diuretics]] || [[Chlorthalidone]] || 12.5, 12.5-25|| rowspan="4" | [[Heart failure]], [[systolic hypertension|isolated systolic hypertension]], black population|| rowspan="4" | [[ACE inhibitors]], [[ARBs]], [[calcium channel blockers]] | ||
|- | |||
|[[Hydrochlorothiazide]] || 12.5-25, 25-100 | |||
|- | |- | ||
|[[Bendroflumethiazide]] || 5, 10 | |||
|- | |- | ||
|[[Indapamide]] || 1.25, 1.25-2.5 | |||
|- | |- | ||
| | | rowspan="3" | [[ACE inhibitors]] || [[Enalapril]] || 5, 20|| rowspan="3" | [[Left ventricular hypertrophy]], [[atherosclerosis]], [[renal insufficiency]], previous [[myocardial infarction]], [[heart failure]], [[atrial fibrillation]] (prevention), [[peripheral artery disease]], [[metabolic syndrome]], [[diabetes mellitus]]|| rowspan="3" | [[Calcium channel blockers]], [[thiazide diuretics]] | ||
|- | |- | ||
| [[ | |[[Lisinopril]] || 10, 40 | ||
|- | |- | ||
|[[Captopril]] || 50, 150-200 | |||
|- | |- | ||
| | | rowspan="5" | [[ARBs]] || [[Candesartan]] || 4, 12-32|| rowspan="5" | [[Left ventricular hypertrophy]], [[renal insufficiency]], previous [[myocardial infarction]], [[heart failure]], [[atrial fibrillation]] (prevention), [[metabolic syndrome]], [[diabetes mellitus]]|| rowspan="5" | [[Calcium channel blockers]], [[thiazide diuretics]] | ||
|- | |- | ||
| [[ | |[[Losartan]] || 50, 100 | ||
|- | |- | ||
|[[Valsartan]] || 40-80, 160-320 | |||
|- | |- | ||
|[[Eprosartan]] || 400, 600-800 | |||
|- | |- | ||
|[[Irbesartan]] || 75, 300 | |||
|- | |- | ||
| | | rowspan="2" | [[Beta blockers]] || [[Atenolol]] || 25-50, 100|| rowspan="2" | Previous [[myocardial infarction]], [[atrial fibrillation]] (prevention and ventricular rate control), [[heart failure]], [[Chronic stable angina|angina pectoris]], [[aortic aneurysm]], [[pregnancy]]|| rowspan="2" | [[Thiazide diuretics]] (with limitations)<br>'''Only [[Calcium channel blocker#Dihydropyridine|dihydropyridine calcium channel blockers]] should be combined with [[beta blockers]]''' | ||
|- | |- | ||
| [[ | |[[Metoprolol succinate]] || 50, 100-200 | ||
|- | |- | ||
| | | rowspan="3" | [[Calcium channel blockers]]|| [[Amlodipine]] || 2.5, 10|| rowspan="3" | [[Left ventricular hypertrophy]], [[pregnancy]] ([[nifedipine]]), previous [[myocardial infarction]], [[atrial fibrillation]] ([[verapamil]], [[diltiazem]]), [[metabolic syndrome]], [[peripheral artery disease]], [[atherosclerosis]], [[Chronic stable angina|angina pectoris]], [[systolic hypertension|isolated systolic hypertension]], black population|| rowspan="3" | [[ACE inhibitors]], [[ARBs]], [[thiazide diuretics]] | ||
|- | |- | ||
| [[ | |[[Diltiazem extended release]] || 120-180, 360 | ||
|- | |- | ||
|[[Nitrendipine]] || 10, 20 | |||
|- | |- | ||
|} | |} | ||
==Don'ts== | ==Don'ts== | ||
* The combination of [[ACE inhibitors]] and [[ARBs]] in a patient is not recommended. | * The combination of [[ACE inhibitors]] and [[ARBs]] in a patient is not recommended.<ref name="DoultonHe2005">{{cite journal|last1=Doulton|first1=Timothy W.R.|last2=He|first2=Feng J.|last3=MacGregor|first3=Graham A.|title=Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension|journal=Hypertension|volume=45|issue=5|year=2005|pages=880–886|issn=0194-911X|doi=10.1161/01.HYP.0000161880.59963.da}}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Resident survival guide]] | [[Category:Resident survival guide]] | ||
Latest revision as of 23:45, 20 August 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]
Hypertension Resident Survival Guide Microchapters |
---|
Overview |
Classification |
Causes |
Diagnosis |
Treatment |
Medical Therapy |
Don'ts |
Overview
Hypertension (HTN) is defined as a systolic blood pressure (SBP) ≥ 140 mmHg and diastolic blood pressure (DBP) ≥ 90 mmHg.[1] It is usually detected during the screening of an asymptomatic individual, but the diagnosis is based on persistent elevation of blood pressure after an average of 2 or more blood pressure measurements taken during 2 or more health care visits. Hypertension is classified as either primary (or essential) when the etiology cannot be identified; or secondary, when the etiology (e.g., hyperthyroidism, pheochromocytoma, renal artery stenosis) is known. The presence of diabetes mellitus, cigarette smoking, excessive sodium intake, obesity, and sedentary lifestyle increases the risk of developing essential hypertension. Lifestyle modifications such as weight reduction, reduction in alcohol consumption, exercises, and reduction in salt intake are recommended to all patients in addition to pharmacological therapy, when required.
Classification
The ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA 2017 clinical practice guidelines[2], executive summary[3], and underlying systematic review[3] by the ACC/AHA taskforce recommend a treatment goal for everyone is <130/80 mm Hg:
Definition | Treatment | |
---|---|---|
Normal blood pressure | <120/80 mmHg | Lifestyle |
Elevated blood pressure | Systolic BP, 120–129 mm Hg - and - Diastolic BP, <80 mm Hg |
Lifestyle |
Stage 1 hypertension | Systolic BP, 130–139 mm Hg - or - Diastolic BP, 80–89 mm Hg |
Lifestyle and Medications if high risk* |
Stage 2 hypertension |
Systolic BP, ≥140 mm Hg - or - Diastolic BP, ≥90 mm Hg |
Lifestyle and Medications |
* High risk defined as existing cardiovascular disease or 10-year cardiovascular risk ≥10% (calculator and alternative calculator with facts box) |
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
- Aortic coarctation
- Cocaine or amphetamine overdose
- Pheochromocytoma
- Preeclampsia
Common Causes
Primary or Essential Hypertension
- No underlying cause is identified. Risk factors include: high sodium intake, obesity, sedentary lifestyle, and excessive alcohol intake.
Secondary Hypertension
- Aortic coarctation
- Chronic kidney disease
- Cocaine or amphetamine overdose
- Cushing's syndrome
- Hyperthyroidism
- Hypothyroidism
- Medications (e.g., oral contraceptive pills, NSAIDs)
- Nephrotic syndrome
- Pheochromocytoma
- Polycystic kidney disease
- Preeclampsia
- Renal artery stenosis
- Sleep apnea
Pseudohypertension
Click here for the complete list of causes.
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.
Boxes in red signify that an urgent management is needed.
For patient presenting with symptoms suggestive of the following: | |||||||||||||||||||||
Measure the blood pressure | |||||||||||||||||||||
BP ≥ 180/120 | BP < 180/120 | ||||||||||||||||||||
Does the patient have any evidence of end organ damage? | Continue with the diagnosis below | ||||||||||||||||||||
Yes | No | ||||||||||||||||||||
Diagnosis
Shown below is an algorithm summarizing the diagnosis of hypertension based on the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and 2013 ESH/ESC guidelines for the management of arterial hypertension.[4][5]
Abbreviations:
ABPM: Ambulatory blood pressure monitoring;
BP: Blood pressure;
CKD: Chronic kidney disease;
DBP: Diastolic blood pressure;
DM: Diabetes mellitus;
SBP: Systolic blood pressure
General Approach
Suspected hypertension BP > 140/90 mmHg | |||||||||||||||||||||||||||||||||||||
Blood pressure measurement Before taking the BP
❑ Take 2 readings and find the average Click here for more information regarding blood pressure measurement | |||||||||||||||||||||||||||||||||||||
For office BP >140/90 mmHg on 2-3 visits | |||||||||||||||||||||||||||||||||||||
Does the patient have any evidence of target organ damage, DM, or CKD? | |||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||
Proceed to hypertensive crisis resident survival guide | Perform home BP/out-of-office monitoring | ||||||||||||||||||||||||||||||||||||
Is the average home BP measurement <140/90? | |||||||||||||||||||||||||||||||||||||
Yes | Inconclusive | No | |||||||||||||||||||||||||||||||||||
Perform 24-hour ABPM | |||||||||||||||||||||||||||||||||||||
Is the 24-hour ABPM ≤135/85? | |||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||
Hypertension confirmed | |||||||||||||||||||||||||||||||||||||
White coat hypertension confirmed | |||||||||||||||||||||||||||||||||||||
Classify the patient based on the BP reading | |||||||||||||||||||||||||||||||||||||
SBP 120-139 mmHg DBP 80-89 mmHg | SBP 149-159 mmHg DBP 90-99 mmHg | SBP >160 mmHg DBP >110 mmHg | |||||||||||||||||||||||||||||||||||
Stage 1 hypertension Proceed to the complete diagnostic approach below | |||||||||||||||||||||||||||||||||||||
Complete Diagnostic Approach
Shown below is an algorithm summarizing the diagnosis of hypertension based on the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and 2013 ESH/ESC guidelines for the management of arterial hypertension.[4][5]
Abbreviations:
BMI: Body mass index;
BP: Blood pressure;
CNS: Central nervous system;
CT: Computed tomography;
CVD: Cardiovascular disease;
eGFR: Estimated glomerular filtration rate;
EKG: Electrocardiogram;
HTN: Hypertension;
LVH: Left ventricular hypertrophy;
MI: Myocardial infarction;
NSAIDs: Non steroidal anti-inflammatory drugs;
TSH: Thyroid stimulating hormone;
UTI: Urinary tract infection
Obtain a detailed history: History of present hypertension
❑ Excessive sodium intake >2.4g per day Eyes: Cardiovascular:
Kidneys:
| |||||||||||||||||||
Examine the patient: General examination: Neck:
Respiratory examination:
| |||||||||||||||||||
Order tests: Routine
❑ Serum calcium (high in hyperparathyroidism)
Additional tests based on results of the routine tests above:
❑ 24-hour free urinary cortisol (elevated in Cushing's syndrome)
❑ Chest CT angiography (To evaluate aortic coarctation) | |||||||||||||||||||
Does the patient have an identifiable secondary etiology? | |||||||||||||||||||
No | Yes | ||||||||||||||||||
Primary hypertension | Secondary hypertension | ||||||||||||||||||
Treatment
Shown below is an algorithm summarizing the treatment of hypertension based on the 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8), ESH/ESC guidelines for the management of arterial hypertension, and the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.[1][4][6]
Prehypertension
❑ Initiate lifestyle modification | |||||||||||||
Stage 1 Hypertension
Shown below is an algorithm summarizing the treatment of hypertension based on the 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) and the 2013 ESH/ESC guidelines for the management of arterial hypertension.[6][4]
Abbreviations:
ACEI: ACE inhibitors;
ARBs: Angiotensin II receptor blockers;
BMI: Body mass index;
BP: Blood pressure;
CCBs: Calcium channel blockers;
CKD: Chronic kidney disease;
DASH: Dietary Approaches to Stop Hypertension;
DM: Diabetes mellitus
Initiate lifestyle modification:
❑ Adopt healthy diet
❑ Limit alcohol consumption
❑ Regular aerobic physical activity (brisk walking, jogging, cycling, swimming) for at least 30 mins per day | |||||||||||||||||||||||||||||
Does the patient have DM or CKD? | |||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||
CKD ± DM | DM only | ||||||||||||||||||||||||||||
Consider the race of the patient | |||||||||||||||||||||||||||||
Black population | Non-black population | ||||||||||||||||||||||||||||
Initiate: ❑ Thiazide diuretic alone, OR | |||||||||||||||||||||||||||||
Has the target BP been reached? | |||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||
Click here for further therapeutic options | |||||||||||||||||||||||||||||
Monitoring and follow-up: Monitor:
❑ 3-6 monthly visits when BP goal is achieved
| |||||||||||||||||||||||||||||
Medical Therapy
Choice of Regimen
Assess BP and cardiovascular risk | |||||||||||||||||||||||||||||||||||||||||||||||||
Mild elevation of BP Low CV risk | Severe elevation of BP High CV risk | ||||||||||||||||||||||||||||||||||||||||||||||||
Consider starting with a single agent | Consider 2-drug combination | ||||||||||||||||||||||||||||||||||||||||||||||||
Target BP achieved? | Target BP achieved? | ||||||||||||||||||||||||||||||||||||||||||||||||
Continue with current regimen | Yes | No | No | Yes | Continue with current regimen | ||||||||||||||||||||||||||||||||||||||||||||
Switch to a different drug Titrate until maximum dose is reached, if necessary | Increase dose of present drug and titrate accordingly | Increase dose of present combination | Add a third drug and titrate to maximum dose, if necessary | ||||||||||||||||||||||||||||||||||||||||||||||
If BP goal is not achieved Add a second drug | |||||||||||||||||||||||||||||||||||||||||||||||||
Maximum dose of 2-drug combination reached | |||||||||||||||||||||||||||||||||||||||||||||||||
If BP goal is not achieved Switch to a different 2-drug combination and titrate to the maximum dose, if necessary OR Add a third drug and titrate to the maximum dose, if necessary | |||||||||||||||||||||||||||||||||||||||||||||||||
Drug List
Don'ts
- The combination of ACE inhibitors and ARBs in a patient is not recommended.[7]
References
- ↑ 1.0 1.1 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL; et al. (2003). "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure". Hypertension. 42 (6): 1206–52. doi:10.1161/01.HYP.0000107251.49515.c2. PMID 14656957.
- ↑ Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C; et al. (2017). "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Hypertension. doi:10.1161/HYP.0000000000000065. PMID 29133356.
- ↑ 3.0 3.1 Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C; et al. (2017). "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Hypertension. doi:10.1161/HYP.0000000000000066. PMID 29133354.
- ↑ 4.0 4.1 4.2 4.3 Mancia, G.; Fagard, R.; Narkiewicz, K.; Redán, J.; Zanchetti, A.; Böhm, M.; Christiaens, T.; Cifkova, R.; De Backer, G. (2013). "2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension". J Hypertens. 31 (10): 1925–38. doi:10.1097/HJH.0b013e328364ca4c. PMID 24107724. Unknown parameter
|month=
ignored (help) - ↑ 5.0 5.1 Chobanian, AV.; Bakris, GL.; Black, HR.; Cushman, WC.; Green, LA.; Izzo, JL.; Jones, DW.; Materson, BJ.; Oparil, S. (2003). "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure". Hypertension. 42 (6): 1206–52. doi:10.1161/01.HYP.0000107251.49515.c2. PMID 14656957. Unknown parameter
|month=
ignored (help) - ↑ 6.0 6.1 James, PA.; Oparil, S.; Carter, BL.; Cushman, WC.; Dennison-Himmelfarb, C.; Handler, J.; Lackland, DT.; LeFevre, ML.; MacKenzie, TD. (2014). "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)". JAMA. 311 (5): 507–20. doi:10.1001/jama.2013.284427. PMID 24352797. Unknown parameter
|month=
ignored (help) - ↑ Doulton, Timothy W.R.; He, Feng J.; MacGregor, Graham A. (2005). "Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension". Hypertension. 45 (5): 880–886. doi:10.1161/01.HYP.0000161880.59963.da. ISSN 0194-911X.